A detailed history of Gladstone Institutional Advisory LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Gladstone Institutional Advisory LLC holds 25,790 shares of ABBV stock, worth $4.28 Million. This represents 0.26% of its overall portfolio holdings.

Number of Shares
25,790
Previous 22,363 15.32%
Holding current value
$4.28 Million
Previous $3.47 Million 35.53%
% of portfolio
0.26%
Previous 0.2%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$159.82 - $182.1 $547,703 - $624,056
3,427 Added 15.32%
25,790 $4.7 Million
Q4 2023

Feb 09, 2024

BUY
$137.6 - $154.97 $182,320 - $205,335
1,325 Added 6.3%
22,363 $3.47 Million
Q3 2023

Nov 13, 2023

BUY
$133.59 - $154.65 $207,198 - $239,862
1,551 Added 7.96%
21,038 $3.14 Million
Q2 2023

Aug 10, 2023

SELL
$132.51 - $164.9 $429,199 - $534,111
-3,239 Reduced 14.25%
19,487 $2.63 Million
Q1 2023

May 12, 2023

SELL
$144.61 - $166.54 $177,870 - $204,844
-1,230 Reduced 5.13%
22,726 $3.62 Million
Q4 2022

Feb 01, 2023

SELL
$138.31 - $165.87 $576,614 - $691,512
-4,169 Reduced 14.82%
23,956 $3.87 Million
Q3 2022

Jan 27, 2023

SELL
$134.21 - $153.93 $1.29 Million - $1.48 Million
-9,588 Reduced 25.42%
28,125 $3.78 Million
Q3 2022

Oct 20, 2022

SELL
$134.21 - $153.93 $1.29 Million - $1.48 Million
-9,588 Reduced 25.42%
28,125 $3.78 Million
Q2 2022

Jan 27, 2023

SELL
$137.62 - $174.96 $1.2 Million - $1.53 Million
-8,753 Reduced 18.84%
37,713 $5.78 Million
Q2 2022

Aug 15, 2022

SELL
$137.62 - $174.96 $1.2 Million - $1.53 Million
-8,753 Reduced 18.84%
37,713 $5.78 Million
Q1 2022

Jan 27, 2023

BUY
$131.98 - $163.75 $3.27 Million - $4.06 Million
24,792 Added 114.39%
46,466 $7.53 Million
Q1 2022

May 04, 2022

BUY
$131.98 - $163.75 $3.27 Million - $4.06 Million
24,792 Added 114.39%
46,466 $7.53 Million
Q4 2021

Jan 27, 2023

BUY
$107.43 - $135.93 $664,991 - $841,406
6,190 Added 39.98%
21,674 $2.94 Million
Q4 2021

Feb 11, 2022

BUY
$107.43 - $135.93 $664,991 - $841,406
6,190 Added 39.98%
21,674 $2.94 Million
Q3 2021

Jan 27, 2023

SELL
$106.4 - $120.78 $86,503 - $98,194
-813 Reduced 4.99%
15,484 $1.67 Million
Q3 2021

Nov 15, 2021

SELL
$106.4 - $120.78 $86,503 - $98,194
-813 Reduced 4.99%
15,484 $1.67 Million
Q2 2021

Jan 27, 2023

BUY
$105.21 - $117.21 $484,281 - $539,517
4,603 Added 39.36%
16,297 $1.84 Million
Q2 2021

Aug 13, 2021

BUY
$105.21 - $117.21 $484,281 - $539,517
4,603 Added 39.36%
16,297 $1.84 Million
Q1 2021

Jan 27, 2023

BUY
$102.3 - $112.62 $389,251 - $428,519
3,805 Added 48.23%
11,694 $1.27 Million
Q1 2021

May 17, 2021

BUY
$102.3 - $112.62 $389,251 - $428,519
3,805 Added 48.23%
11,694 $1.27 Million
Q4 2020

Jan 27, 2023

SELL
$80.49 - $108.67 $54,089 - $73,026
-672 Reduced 7.85%
7,889 $845,000
Q4 2020

Feb 16, 2021

SELL
$80.49 - $108.67 $54,089 - $73,026
-672 Reduced 7.85%
7,889 $845,000
Q3 2020

Jan 27, 2023

SELL
$85.91 - $100.83 $1.68 Million - $1.97 Million
-19,564 Reduced 69.56%
8,561 $750,000
Q3 2020

Nov 16, 2020

SELL
$85.91 - $100.83 $738,482 - $866,734
-8,596 Reduced 50.1%
8,561 $750,000
Q2 2020

Aug 17, 2020

BUY
$73.37 - $98.18 $394,290 - $527,619
5,374 Added 45.61%
17,157 $1.68 Million
Q1 2020

May 14, 2020

BUY
$64.5 - $97.79 $200,337 - $303,735
3,106 Added 35.8%
11,783 $898,000
Q4 2019

Feb 12, 2020

SELL
$72.13 - $90.25 $228,363 - $285,731
-3,166 Reduced 26.73%
8,677 $768,000
Q3 2019

Nov 13, 2019

SELL
$62.98 - $75.72 $11,777 - $14,159
-187 Reduced 1.55%
11,843 $897,000
Q2 2019

Aug 14, 2019

BUY
$65.7 - $83.98 $556,413 - $711,226
8,469 Added 237.83%
12,030 $875,000
Q1 2019

May 10, 2019

SELL
$77.14 - $90.79 $8,253 - $9,714
-107 Reduced 2.92%
3,561 $287,000
Q4 2018

Feb 13, 2019

BUY
$77.85 - $96.01 $285,553 - $352,164
3,668 New
3,668 $338,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $293B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Gladstone Institutional Advisory LLC Portfolio

Follow Gladstone Institutional Advisory LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gladstone Institutional Advisory LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gladstone Institutional Advisory LLC with notifications on news.